$PLSE News
Last published 1w ago
- 1w agoPLSEPULSE BIOSCIENCES, INC. - PRESS RELEASE ISSUED BY PULSE BIOSCIENCES, INC. DATED NOVEMBER 5, 2026 - BUSINESEarnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 1w agoPLSEPulse Biosciences Q3 2026 Earnings Call - PULSE BIOSCIENCES INCEarnings Call TranscriptsThank you for standing by. My name is Cass and I will be your conference operator today. At this time, I would like to welcome everyone to the Pulse Biosciences 3rd Quarter 2026 Orange Call. All lines have been placed on
- 2w agoPLSEPulse Biosciences to Present at Stifel 2026 Healthcare ConferenceBusiness WirePulse Biosciences, Inc. (NASDAQ:PLSE), the company leveraging its ever evolving novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced plans to participate in the
- 3w agoPLSEPulse Biosciences Schedules Third Quarter 2026 Financial Results Conference Call for November 5, 2026Business WirePulse Biosciences, Inc. (NASDAQ:PLSE), the company leveraging its ever evolving novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced it will report business updates
- 4w agoPLSEPulse Biosciences Announces Commercial and Clinical Partnership with the Clayman Thyroid CenterBusiness WireCollaboration adds the nPulse™ Vybrance™ System to patient care at the Hospital for Endocrine Surgery and supports generation of additional clinical data Pulse Biosciences, Inc. (NASDAQ:PLSE), the company leveraging
- 1mo agoPLSEPulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WirePulse Biosciences, Inc. (NASDAQ:PLSE), the company leveraging its ever evolving novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced that the Compensation Committee
- 1mo agoPLSEPulse Biosciences’ nPulse™ Technology to be Featured at the 21st Annual International VT Symposium 2026Business WirePreclinical evaluation of nPulse™ prototype endocardial catheters highlighted in session presentation Pulse Biosciences, Inc. (NASDAQ:PLSE), the company leveraging its ever evolving novel and proprietary Nanosecond
- 1mo agoPLSEPulse Biosciences Achieves Enrollment Target in NANOPULSE-AF IDE Pivotal Clinical Study Evaluating nPulse™ Cardiac Catheter System for Atrial Fibrillation TreatmentBusiness Wire164 evaluable patients enrolled across 15 clinical sites Pulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today
- 1mo agoPLSEPulse Biosciences Completes Enrollment in the PRECISE-BTN Clinical Study Evaluating the nPulse™ Vybrance™ Percutaneous Electrode System for Symptomatic Benign Thyroid NodulesBusiness WireCompleted 100 patient enrollment across three U.S. sites; first patient enrolled completed 12-month follow-up Pulse Biosciences, Inc. (NASDAQ:PLSE), developer of the novel nPulse™ technology using proprietary
- 2mo agoPLSEPulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WirePulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced that the Compensation Committee of its Board of
- 2mo agoPLSEPulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WirePulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced that the Compensation Committee of its Board of
- 3mo agoPLSECG 46TH ANNUAL GROWTH CONFERENCE - PULSE BIOSCIENCES INCEarnings Call TranscriptsAll right, good afternoon. Welcome to the Canaccord Genuity 46th Annual Global Growth Conference. My name is Bill Plovonik. I'm a Senior Medical Device Analyst here with Canaccord. With us up next, we have industry legen
- 3mo agoPLSEPulse Biosciences Q2 2026 Earnings Call - PULSE BIOSCIENCES INCEarnings Call TranscriptsThank you for standing by. My name is Tina, and I will be your conference operator today. At this time, I would like to welcome everyone to the Pulse Biosciences Q2 2026 earnings call. All lines have been placed on mute
- 3mo agoPLSEPulse Biosciences Reports Business Updates and Second Quarter 2026 Financial ResultsBusiness WirePulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced business updates and financial results for the
- 3mo agoPLSEPulse Biosciences to Present at Canaccord Genuity’s 46th Annual Growth ConferenceBusiness WirePulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced plans to participate in the upcoming Canaccord
- 3mo agoPLSEPulse Biosciences Surpasses Enrollment Midpoint in NANOPULSE-AF IDE Pivotal StudyBusiness WirePulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced that the NANOPULSE-AF Study has surpassed its
- 3mo agoPLSEPulse Biosciences Schedules Second Quarter 2026 Financial Results Conference Call for August 6, 2026Business WirePulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced it will report business updates and financial
- 4mo agoPLSEPulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WirePulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced that the Compensation Committee of its Board of
- 5mo agoPLSEGoldman Sachs 47th Annual Global Healthcare ConferencePULSE BIOSCIENCES INCEarnings Call TranscriptsCool. We'll go ahead and get started here with our next presentation. Very pleased to have a management team from Pulse Biosciences, Paula Violet, President, CEO, and Chairman here today to talk about the business. I mak
- 5mo agoPLSEPulse Biosciences, Inc. Announces Planned Redemption of WarrantsBusiness WirePulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced that it intends to deliver an
- 5mo agoPLSEPulse Biosciences to Present at the Goldman Sachs 47th Annual Global Healthcare Conference 2026Business WirePulse Biosciences, Inc. (NASDAQ:PLSE), developer of nPulse™ technology using proprietary nanosecond pulsed field ablation (nsPFA™) energy, today announced plans to participate in the upcoming Goldman Sachs
- 6mo agoPLSE2026 GLOBAL HEALTHCARE CONFERENCEPULSE BIOSCIENCES INCEarnings Call TranscriptsAll right. Thank you, everybody, for joining Day 2 here at the Bank of America Healthcare Conference. I'm Dan Loquist, the healthcare specialist. I'm very pleased today to have the team from Pulse Biosciences, where I'm
- 6mo agoPLSEATM Equity Purchases by Pulse Biosciences' Co-Chairmen Total Approximately $13.3 MillionBusiness WirePulse Biosciences, Inc. (NASDAQ:PLSE), developer of nPulse™ technology using proprietary nanosecond pulsed field ablation (nsPFA™) energy, today announced its Co-Chairmen of the Board, Robert Duggan and
- 6mo agoPLSEPulse Biosciences to Present at the BofA Securities 2026 Healthcare ConferenceBusiness WirePulse Biosciences, Inc. (NASDAQ:PLSE), developer of nPulse™ technology using proprietary nanosecond pulsed field ablation (nsPFA™) energy, today announced plans to participate in the upcoming BofA
- 6mo agoPLSEPulse Biosciences Reports Business Updates and First Quarter 2026 Financial ResultsBusiness WireAccelerates Enrollment Timeline for the Cardiac Catheter IDE Conference Call to Be Held Thursday, May 7th to Discuss Business Updates and Financial Results Pulse Biosciences, Inc. (NASDAQ:PLSE), developer of novel
- 6mo agoPLSEPulse Biosciences Presents Positive Outcomes in Late-Breaking Updated Data from nPulse™ Cardiac Catheter System at Heart Rhythm 2026Business WireMulticenter results show sustained high durability and procedural efficiency, redefining positive expectations for catheter ablation in patients with atrial fibrillation Pulse Biosciences, Inc. (NASDAQ:PLSE),
- 6mo agoPLSEPulse Biosciences' nPulse™ Technology to be Featured at the Heart Rhythm Society 2026 Annual MeetingBusiness WirenPulse™ Technology highlighted in late-breaking feasibility study and live case transmission Pulse Biosciences, Inc. (NASDAQ:PLSE), developer of nPulse™ technology using proprietary nanosecond pulsed
- 6mo agoPLSEPulse Biosciences to Host Analyst Event on April 25, 2026Business WireManagement to discuss late-breaking data and the clinical program for its nPulse Cardiac Catheter System Pulse Biosciences, Inc. (NASDAQ:PLSE), developer of nPulse™ technology using proprietary nanosecond
- 7mo agoPLSE25th Annual Needham Virtual Healthcare Conference - PULSE BIOSCIENCES INCEarnings Call TranscriptsGood morning. Thanks for joining us again at the 25th Annual Neom Healthcare Conference. I'm Mike Madsen, and I lead the MedTech and Diagnostics Equity Research Team at Neom and Company. I'm pleased to introduce Pulse Bi
- 7mo agoPLSEPulse Biosciences Strengthens Executive Leadership TeamBusiness WireAppoints Liane Teplitsky as Chief Operating Officer Expands Dr. David Kenigsberg's Chief Medical Officer Role Pulse Biosciences, Inc. (NASDAQ:PLSE), developer of nPulse™ technology using proprietary
- 7mo agoPLSEPulse Biosciences Enrolls First Patients in NANOPULSE-AF IDE Pivotal Clinical Study Evaluating nPulse™ Cardiac Catheter System for Atrial FibrillationBusiness WireU.S. IDE Enrollment follows groundbreaking 96% procedural success at 12 months in European feasibility study Pulse Biosciences, Inc. (NASDAQ:PLSE), developer of nPulse™ technology using proprietary nanosecond
- 7mo agoPLSEPulse Biosciences to Present at the 25th Annual Needham Virtual Healthcare ConferenceBusiness WirePulse Biosciences, Inc. (NASDAQ:PLSE), pioneer of the novel nPulse™ platform using proprietary Nanosecond Pulsed Field Ablation (nsPFA™), today announced plans to present at the upcoming 25th Annual
- 7mo agoPLSEOPPENHEIMER 36TH ANNUAL HEALTHCARE MEDTECH & SERVICES CONFERENCE - PULSE BIOSCIENCES INCEarnings Call TranscriptsGood morning, everyone. Siraj Kavya, Senior Medical Device Analyst at Oppenheimer. Pleased to have with us this morning management from Pulse Biosciences CEO, Paul Avialet, who I've known for more than a decade, and CFO,
- 8mo agoPLSEPulse Biosciences Announces Strategic Alignment to Accelerate Cardiac Catheter Program Following Exceptional Long-Term AFib Clinical DataBusiness WirePulse Biosciences, Inc. (NASDAQ:PLSE), pioneer of the novel nPulse™ platform using proprietary Nanosecond Pulsed Field Ablation (nsPFA™), today announced a new strategic alignment to prioritize and
- 8mo agoPLSEPulse Biosciences, Inc. Announces First Enrollments in Feasibility Study for the Treatment of Malignant Thyroid Tumors with nPulse™ TechnologyBusiness WirePulse Biosciences, Inc. (NASDAQ:PLSE), developer of the novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced first
- 8mo agoPLSEPulse Biosciences Announces Clinical Data From nPulse™ Vybrance™ System First-In-Human Clinical Durability Study of Benign Thyroid Nodule AblationBusiness WireDurable volume reduction was demonstrated with an average volume reduction of 74% of treated benign thyroid nodules at 15-22 months post-treatment. Pulse Biosciences, Inc. (NASDAQ:PLSE), developer of the novel
- 8mo agoPLSEPulse Biosciences to Present at the Oppenheimer 36th Annual Healthcare MedTech & Services ConferenceBusiness WirePulse Biosciences, Inc. (NASDAQ:PLSE), developer of the novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced plans to
- 8mo agoPLSETD COWEN 46TH ANNUAL HEALTH CARE CONFERENCE - PULSE BIOSCIENCES INCEarnings Call TranscriptsOkay, good afternoon. I'm Josh Jennings from the TD Cowan Medical Devices Research Team, and we are very excited to have executives from Pulse Biosciences participate again this year. I want to introduce CEO Paul LaViole
- 8mo agoPLSEPulse Biosciences' nPulse™ Vybrance™ System to be Featured in Multiple Presentations at the North American Society for Interventional Thyroidology MeetingBusiness WirenPulse™ Vybrance™ System for soft tissue ablation, such as benign thyroid ablation, to be highlighted in podium presentation and product theatre presentation Pulse Biosciences, Inc. (NASDAQ:PLSE),
- 8mo agoPLSEPulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WirePulse Biosciences, Inc. (NASDAQ:PLSE), developer of the novel nPulse™ technology using proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced that the
- 8mo agoPLSEPulse Biosciences to Present at the 46th Annual TD Cowen Healthcare ConferenceBusiness WirePulse Biosciences, Inc. (NASDAQ:PLSE), developer of the novel nPulse™ technology using proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced plans to
- 8mo agoPLSEPulse Biosciences Q4 and Full Year 2025 Earnings Call - PULSE BIOSCIENCES INCEarnings Call TranscriptsLadies and gentlemen, thank you for standing by. My name is Colby and I will be your conference operator today. At this time, I would like to welcome you to the Pulse Biosciences Q4 and full year 2025 earnings call. All
- 8mo agoPLSEPulse Biosciences Reports Business Updates and Fourth Quarter & Full Year 2025 Financial ResultsBusiness WirePulse Biosciences, Inc. (NASDAQ:PLSE), developer of the novel nPulse™ technology using proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced business
- 9mo agoPLSEPulse Biosciences Presents Late-Breaking Data from nPulse™ Cardiac Catheter System First-In-Human Feasibility Study at the AF SymposiumBusiness WireProcedural success was achieved in 100% of evaluable patients at 6 months and 96% in 12 months Pulse Biosciences, Inc. (NASDAQ:PLSE), developer of the novel nPulse™ technology using proprietary Nanosecond
- 9mo agoPLSEPulse Biosciences Schedules Fourth Quarter & Full Year 2025 Financial Results Conference Call for February 19, 2026Business WirePulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced it
- 9mo agoPLSEPulse Biosciences' nPulse™ Cardiac Catheter to Be Featured in Multiple Presentations at the AF SymposiumBusiness WirenPulse Cardiac Catheter for AF ablation to be highlighted in late-breaking clinical science session and in a live case transmission Pulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel nPulse™
- 10mo agoPLSEPulse Biosciences to Present at the 44th Annual J.P. Morgan Healthcare ConferenceBusiness WirePulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced
- 10mo agoPLSEPulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WirePulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced
- 10mo agoPLSEPulse Biosciences Announces FDA IDE Approval to Initiate its nPulse Cardiac Catheter Ablation System Study for the Treatment of Atrial FibrillationBusiness WirePulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced
- 11mo agoPLSEPulse Biosciences, Inc. Announces Initiation of Research Collaboration for the Treatment of Benign and Malignant Thyroid Tumors with nPulse™ TechnologyBusiness WirePulse Biosciences, Inc. (NASDAQ:PLSE) (the "Company" or "Pulse Biosciences"), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or